ミルリノン
ミルリノン · ミルリーラ-K · 1,6-ジヒドロ-2-メチル-6-オキソ[3,4'-ビピリジン]-5-カルボニトリル · ミルリーラ · 2-オキソ-5-(4-ピリジル)-6-メチル-1,2-ジヒドロピリジン-3-カルボニトリル · 3-シアノ-5-(4-ピリジル)-6-メチル-2(1H)-ピリドン · 1,6-ジヒドロ-2-メチル-6-オキソ-3,4'-ビピリジン-5-カルボニトリル · 3-シアノ-6-メチル-5-(4-ピリジル)-2-ピリドン
識別子と物理属性
| CAS No. | 78415-72-2 |
|---|---|
| 分子式 | C12H9N3O |
| 平均分子量 | 211.22 g/mol |
| 単同位体質量 | 211.07456191 g/mol |
| SMILES | Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1 |
| InChIKey | PZRHRDRVRGEVNW-UHFFFAOYSA-N |
| PubChem CID | 4197 |
| ChEMBL | CHEMBL189 |
| ChEBI | CHEBI:50693 |
| EC No. | 278-903-6 |
| DTXSID | DTXSID5023324 |
| 現地名 | ミルリノン |
化学・物理的性質
| XLogP | 0 |
|---|---|
| 極性表面積 | 65.8 |
| 水素結合供与体数 | 1 |
| 水素結合受容体数 | 3 |
| 回転可能結合数 | 1 |
| 重原子数 | 16 |
| 形式電荷 | 0 |
| 複雑度 | 419 |
| 医薬品 | PharmaceuticalsPharmaceuticals -> Listed in ZINC15 |
| LogP（分配係数） | 0.40.42 |
| 溶解度 | <1 mg/mL2.09e-01 g/LDMSO: >10 mg/mLDMSOに可溶。水に不溶。 |
| Human Drugs | Pharmaceuticals |
| 融点 | >300 °C> 300 °C>3000C |
| Physical Description | Solid |
| Collision Cross Section | 157.1 Ų [M+H]+ [CCS Type: DTBuffer gas: N2Ionization: APCI+Dataset: TOXCASTSource Identifier: DTXSID5023324]150.4 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)] |
| 沸点 | 350.9°C (rough estimate) |
| 密度 | 1.1922 (rough estimate) |
| 屈折率 | 1.5700 (estimate) |
| 貯蔵条件 | 2-8°C |
| 外観・状態 | 粉 |
| pKa（酸解離定数） | 7.21±0.10(Predicted) |
| 色 | オフホワイト |
| Merck | 14,6197 |
| 安定性 | 安定。強力な酸化剤とは相容れない。 |
| InChI | InChI=1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16) |
| InChIKey | FYEJSUDMDUIMKJ-UHFFFAOYSA-N |
| SMILES | C1(C)NC(=O)C(C#N)=CC=1C1C=CN=CC=1 |
| CAS データベース | 78415-72-2(CAS DataBase Reference) |
化学的特性
Crystalline Solid
安全性と法規制
| GHS 分類 | DangerH301+H311+H331 (38.4%): Toxic if swallowed, in contact with skin or if inhaled [Danger Acute toxicity, oralacute toxicity, dermalacute toxicity, inhalation]P261, P262, P264, P270, P271, P280, P301+P316, P302+P352, P304+P340, P316, P321, P330, P361+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 73 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 3 (100%) |
| 有害作用 | The most feared adverse effect of milrinone is its potential to induce hemodynamic changes and arrhythmias. Milrinone may cause ventricular tachyarrhythmia, leading to cardiac ischemia or sudden cardiac death. These changes are not shown to follow a dose-dependent relationship. Milrinone can cause an increase in venous vessel capacitance, leading to decreased preload and manifesting as headaches, syncope, and severe hypotension. Unlike tachyarrhythmias, hypotension occurs in a dose-dependent relationship. |
| 毒性の概要 | Cardiovascular toxicity is primarily seen in chronically milrinone patients and manifests as tachyarrhythmias and sudden cardiac death. At high dosing, patients may also experience hypotension and syncope. Milrinone had a previous use as an oral formulation for outpatient use in patients with NYHA class III and IV chronic heart failure (CHF) to improve symptoms and decrease the frequency of hospital admissions. However, this practice was discontinued following the PROMISE trial in 1991 due to safety concerns. This double-blinded clinical trial assessed patients with CHF class III/IV placed on milrinone or placebo and ended early due to increased mortality in the milrinone group secondary to ventricular tachyarrhythmias and sudden cardiac death. |
| 水環境危害等級（WGK） | 3 |
| RTECS 番号 | DW1762000 |
| 輸送番号（UN） | UN 2811 6.1/PG 3 |
| 税関コード | 29337900 |
| 危険文句（R） | 23/24/25-26/27/28 |
| 危険表示 | T,T+ |
| 安全措置（S） | 36/37/39-45-22 |
| 危険等級 | 6.1(b)Acute Tox. 3 Oral |
| 包装等級 | III |
| 毒劇物取締法 | 劇物 |
| 貯蔵分類 | 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects |
用途
用途
cGMP 阻害性ホスホジエステ ラーゼ（PDE Ⅲ）を選択的に阻害します。
用途
cGMP阻害性ホスホジエステ ラーゼ（PDEⅢ）を選択的に阻害します。
説明
Milrinone, an inhibitor of phosphodiesterase selective for fraction III PDE, exerts a positive inotropic effect on the heart as well as a peripheral vasodilatory effect. Milrinone given intravenously produces significant improvements on cardiac output, pulmonary capillary wedge pressure and vascular resistance without significant effects on the heart rate.
使用
It is used (particularly intravenously, as the lactate) for the short-term management of severe heart failure. Milrinone inhibits the action of phosphodiesterase-3 preventing degradation of cAMP. The corresponding increase in cAMP levels leads to increased activation of protein kinase A. It is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity.
一般的な説明
Milrinone, 1,6-dihydro-2-methyl-6-oxo-3,4＇-bipyridine-5-carbonitrile (Primacor), is another dipyridinephosphodiesterase F-III inhibitor that possesses pharmacologicalproperties similar to those of amrinone. The inhibitionof the degradation of cAMP results in an increase in the cardiacmuscle’s force of contraction.